{{if listFind(vars.channel_names, "MSIF News")}}

{{endif}}

{{if listFind(vars.channel_names, "MSIF News")}}

{{endif}}

{{if listFind(vars.channel_names, "People With MS News")}}

{{endif}}

{{if listFind(vars.channel_names, "People With MS News")}}

{{endif}}

{{if listFind(vars.channel_names, "Research News")}}

{{endif}}

{{if listFind(vars.channel_names, "Research News")}}

{{endif}}

{{if listFind(vars.channel_names, "MS Society News")}}

{{endif}}

{{if listFind(vars.channel_names, "MS Society News")}}

{{endif}}

More language versions of MS in focus now available

MS in focus issue five on healthy living is now available in Italian and French, and issues six (intimacy and sexuality), seven (rehabilitation) and eight (genetics) are available in Italian.

read more

back to top

Profile of the Month : January 2009

Kürşat Korkut

Age: 39
Country: Turkey
Type of MS: RRMS
Year of diagnosis: 2002

I believe that we will beat MS, and encourage you to live your life and don't let MS overcome you.

Read the full article here:

English Espanol Italiano Francais Deutsch Русский

read more

back to top

Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS

In this randomised single-blind study, the authors demonstrated that mitoxantrone followed by glatiramer was more effective in suppressing inflammation on MRI than glatiramer on its own.

authors: Arnold DL, Campagnolo D, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Vollmer T

source: J Neurol. 2008 Oct 7

read more

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis

In this study the authors found changes in the T cells in the blood, a type of cell involved in the immune response, in people who received a new tablet medication called FTY720 which is under investigation in MS.

authors: Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, Vedrine C, Kristofic C, Kuhle J, Lindberg RL, Kappos L

source: Neurology 2008 Oct 14;71(16):1261-7

read more

Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab

Natalizumab is a new medication for MS, which is very effective at reducing inflammation but can have serious side effects. In this pathological study the effects of natalizumab on certain areas of the brain were investigated and differences in the immune cells were found, which might partly explain the prolonged effects of the medication.

authors: Martin MD, Cravens PD, Winger R, Frohman EM, Racke MK, Eagar TN, Zamvil SS, Weber MS, Hemmer B, Karandikar NJ, Kleinschmidt-Demasters BK, Stüve O

source: Arch Neurol. 2008 Oct 13

read more

The association of nocturnal serum melatonin levels with major depression in patients with acute multiple sclerosis

In this uncontrolled study depression in people with MS was investigated and found to be related with levels of a hormone called melatonin. This might be useful in designing future treatments.

authors: Akpınar Z, Tokgöz S, Gökbel H, Okudan N, Uğuz F, Yılmaz G

source: Psychiatry Res. 2008 Oct 9

read more

Spinal cord grey matter lesions in multiple sclerosis detected by post-mortem high field MR imaging

In this study pathological specimens were compared with MRI. The authors reported that spinal cord MRI appears particularly sensitive to detecting grey matter lesions in MS.

authors: Gilmore C, Geurts J, Evangelou N, Bot J, van Schijndel R, Pouwels P, Barkhof F, Bö L

source: Mult Scler. 2008 Oct 9

read more

Patient education program to enhance decision autonomy in multiple sclerosis relapse management: a randomized-controlled trial

In this randomised-controlled trial the authors demonstrated effectiveness of an education programme in people with MS in which they were involved in managing their own relapses.

authors: Köpke S, Kasper J, Mühlhauser I, Nübling M, Heesen C

source: Mult Scler. 2008 Oct 9

read more

Quantitative PCR for Epstein-Barr virus DNA and RNA in multiple sclerosis

The causes of MS are complex and viruses may play a role. In this study the authors compared the levels of Epstein-Barr virus present in the blood of people with MS and healthy controls. There were no differences between the two groups.

authors: Lindsey J, Hatfield L, Crawford M, Patel S

source: Mult Scler. 2008 Oct 9

read more

Spectrum of pediatric neuromyelitis optica

The authors of this study described the clinical features of a group of children with neuromyelitis optica, a very similar disease to multiple sclerosis. They concluded that early diagnosis is important in order to start treatment to improve the outcome.

authors: Lotze TE, Northrop JL, Hutton GJ, Ross B, Schiffman JS, Hunter JV

source: Pediatrics 2008 Oct 6

read more

back to top

Teams funded by National MS Society USA report on key enzymes related to MS progression and nervous system repair

source: National MS Society USA

Researchers funded by the National MS Society USA have reported findings on nerve tissue injury and repair.

read more

Take part in the MS Society of India's MS Walk in Mumbai, 16 November 2008

source: MS Society of India

The MS Society of India (MSSI) Mumbai Chapter invites you to participate in the MS Walk at the Dadar Parsi Colony Gymkhana, Mumbai, on 16 November 2008.

read more

Guide to clinical trials for people with MS now available in Spanish

source: National MS Society USA

The National MS Society USA has produced a guide to clinical trials for people with MS in Spanish as part of its initiative to support Hispanic communities across the region.

read more

back to top

Tell a friend

The email you subscribed with us is {{print email}}

Within this newsletter the following options are available: MSIF News; People with MS News; Research News and MS Society News. To amend your options please login to the 'My world of MS' online community where you can also read diary entries from people affected by MS, leave your own diary entries and send messages to other users. You can also change your email address, contact details and subscribe to our free publications.

If you have an RSS News Reader you can get the latest news syndicated to you by copying the following link to your Reader: Syndicate.

If you do not want to receive future issues of this newsletter or if you have received this in error, please accept our apologies and simply unsubscribe here

Multiple Sclerosis International Federation
3rd Floor Skyline House, 200 Union Street, SE1 0LX
Tel: +44 (0) 20 7620 1911
Fax: +44 (0) 20 7620 1922
Registered Charity: 1105321
Email: info@msif.org

 Click here to learn more about the work of the Making Connections sponsor.